These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 35091749)

  • 21. QT effects of bedaquiline, delamanid, or both in patients with rifampicin-resistant tuberculosis: a phase 2, open-label, randomised, controlled trial.
    Dooley KE; Rosenkranz SL; Conradie F; Moran L; Hafner R; von Groote-Bidlingmaier F; Lama JR; Shenje J; De Los Rios J; Comins K; Morganroth J; Diacon AH; Cramer YS; Donahue K; Maartens G;
    Lancet Infect Dis; 2021 Jul; 21(7):975-983. PubMed ID: 33587897
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Verapamil Increases the Bioavailability and Efficacy of Bedaquiline but Not Clofazimine in a Murine Model of Tuberculosis.
    Xu J; Tasneen R; Peloquin CA; Almeida DV; Li SY; Barnes-Boyle K; Lu Y; Nuermberger E
    Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29038265
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Detection of a historic reservoir of bedaquiline/clofazimine resistance-associated variants in Mycobacterium tuberculosis.
    Nimmo C; Ortiz AT; Tan CCS; Pang J; Acman M; Millard J; Padayatchi N; Grant AD; O'Donnell M; Pym A; Brynildsrud OB; Eldholm V; Grandjean L; Didelot X; Balloux F; van Dorp L
    Genome Med; 2024 Feb; 16(1):34. PubMed ID: 38374151
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A mutation associated with clofazimine and bedaquiline cross-resistance in MDR-TB following bedaquiline treatment.
    Somoskovi A; Bruderer V; Hömke R; Bloemberg GV; Böttger EC
    Eur Respir J; 2015 Feb; 45(2):554-7. PubMed ID: 25359333
    [No Abstract]   [Full Text] [Related]  

  • 25. Cross-resistance between clofazimine and bedaquiline through upregulation of MmpL5 in Mycobacterium tuberculosis.
    Hartkoorn RC; Uplekar S; Cole ST
    Antimicrob Agents Chemother; 2014 May; 58(5):2979-81. PubMed ID: 24590481
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mutations associated with in vitro resistance to bedaquiline in Mycobacterium tuberculosis isolates in Australia.
    Martinez E; Hennessy D; Jelfs P; Crighton T; Chen SC; Sintchenko V
    Tuberculosis (Edinb); 2018 Jul; 111():31-34. PubMed ID: 30029911
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics of bedaquiline, delamanid and clofazimine in patients with multidrug-resistant tuberculosis.
    Alghamdi WA; Al-Shaer MH; Kipiani M; Barbakadze K; Mikiashvili L; Kempker RR; Peloquin CA
    J Antimicrob Chemother; 2021 Mar; 76(4):1019-1024. PubMed ID: 33378452
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Bedaquiline, Pyrazinamide, Levofloxacin, Linezolid, and Clofazimine Second-line Regimen for Tuberculosis Displays Similar Early Bactericidal Activity as the Standard Rifampin-Based First-line Regimen.
    Zainabadi K; Vilbrun SC; Mathurin LD; Walsh KF; Pape JW; Fitzgerald DW; Lee MH
    J Infect Dis; 2024 Aug; 230(2):e447-e456. PubMed ID: 38060827
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A bedaquiline/clofazimine combination regimen might add activity to the treatment of clinically relevant non-tuberculous mycobacteria.
    Ruth MM; Sangen JJN; Remmers K; Pennings LJ; Svensson E; Aarnoutse RE; Zweijpfenning SMH; Hoefsloot W; Kuipers S; Magis-Escurra C; Wertheim HFL; van Ingen J
    J Antimicrob Chemother; 2019 Apr; 74(4):935-943. PubMed ID: 30649327
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A case of primary multidrug-resistant pulmonary tuberculosis with high minimum inhibitory concentration value for bedaquiline.
    Kobayashi M; Motoki Y; Yamagishi T; Hirano H; Nonaka M; Aono A; Mitarai S; Saito T
    J Infect Chemother; 2022 Aug; 28(8):1193-1197. PubMed ID: 35550867
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efflux inhibition with verapamil potentiates bedaquiline in Mycobacterium tuberculosis.
    Gupta S; Cohen KA; Winglee K; Maiga M; Diarra B; Bishai WR
    Antimicrob Agents Chemother; 2014; 58(1):574-6. PubMed ID: 24126586
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MmpR5 protein truncation and bedaquiline resistance in Mycobacterium tuberculosis isolates from South Africa: a genomic analysis.
    Roberts LW; Malone KM; Hunt M; Joseph L; Wintringer P; Knaggs J; Crook D; Farhat MR; Iqbal Z; Omar SV
    Lancet Microbe; 2024 Aug; 5(8):100847. PubMed ID: 38851206
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bedaquiline: a novel antitubercular agent for the treatment of multidrug-resistant tuberculosis.
    Worley MV; Estrada SJ
    Pharmacotherapy; 2014 Nov; 34(11):1187-97. PubMed ID: 25203970
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bedaquiline safety, efficacy, utilization and emergence of resistance following treatment of multidrug-resistant tuberculosis patients in South Africa: a retrospective cohort analysis.
    Pai H; Ndjeka N; Mbuagbaw L; Kaniga K; Birmingham E; Mao G; Alquier L; Davis K; Bodard A; Williams A; Van Tongel M; Thoret-Bauchet F; Omar SV; Bakare N
    BMC Infect Dis; 2022 Nov; 22(1):870. PubMed ID: 36414938
    [TBL] [Abstract][Full Text] [Related]  

  • 35. atpE Mutation in Mycobacterium tuberculosis Not Always Predictive of Bedaquiline Treatment Failure.
    Le Ray LF; Aubry A; Sougakoff W; Revest M; Robert J; Bonnet I; Veziris N; Morel F
    Emerg Infect Dis; 2022 May; 28(5):1062-1064. PubMed ID: 35447056
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Outcomes of Bedaquiline Treatment in Patients with Multidrug-Resistant Tuberculosis.
    Mbuagbaw L; Guglielmetti L; Hewison C; Bakare N; Bastard M; Caumes E; Fréchet-Jachym M; Robert J; Veziris N; Khachatryan N; Kotrikadze T; Hayrapetyan A; Avaliani Z; Schünemann HJ; Lienhardt C
    Emerg Infect Dis; 2019 May; 25(5):936-943. PubMed ID: 31002070
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Multidrug Resistant Tuberculosis With Simultaneously Acquired Drug Resistance to Bedaquiline and Delamanid.
    Yoshiyama T; Takaki A; Aono A; Mitarai S; Okumura M; Ohta K; Kato S
    Clin Infect Dis; 2021 Dec; 73(12):2329-2331. PubMed ID: 32730621
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bactericidal activity of pyrazinamide and clofazimine alone and in combinations with pretomanid and bedaquiline.
    Diacon AH; Dawson R; von Groote-Bidlingmaier F; Symons G; Venter A; Donald PR; van Niekerk C; Everitt D; Hutchings J; Burger DA; Schall R; Mendel CM
    Am J Respir Crit Care Med; 2015 Apr; 191(8):943-53. PubMed ID: 25622149
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bedaquiline- and clofazimine- selected Mycobacterium tuberculosis mutants: further insights on resistance driven largely by Rv0678.
    Snobre J; Villellas MC; Coeck N; Mulders W; Tzfadia O; de Jong BC; Andries K; Rigouts L
    Sci Rep; 2023 Jun; 13(1):10444. PubMed ID: 37369740
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bedaquiline Drug Resistance Emergence Assessment in Multidrug-Resistant Tuberculosis (MDR-TB): a 5-Year Prospective
    Kaniga K; Hasan R; Jou R; Vasiliauskienė E; Chuchottaworn C; Ismail N; Metchock B; Miliauskas S; Viet Nhung N; Rodrigues C; Shin S; Simsek H; Smithtikarn S; Ngoc ALT; Boonyasopun J; Kazi M; Kim S; Kamolwat P; Musteikiene G; Sacopon CA; Tahseen S; Vasiliauskaitė L; Wu MH; Vally Omar S
    J Clin Microbiol; 2022 Jan; 60(1):e0291920. PubMed ID: 34705538
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.